Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

736 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Translational Modeling Predicts Efficacious Therapeutic Dosing Range of Teclistamab for Multiple Myeloma.
Girgis S, Lin SXW, Pillarisetti K, Banerjee A, Stephenson T, Ma X, Shetty S, Yang TY, Hilder BW, Jiao Q, Hanna B, Adams HC 3rd, Sun YN, Sharma A, Smit J, Infante JR, Goldberg JD, Elsayed Y. Girgis S, et al. Among authors: jiao q. Target Oncol. 2022 Jul;17(4):433-439. doi: 10.1007/s11523-022-00893-y. Epub 2022 Jun 24. Target Oncol. 2022. PMID: 35749004 Free PMC article. Clinical Trial.
Correction: Translational Modeling Predicts Efficacious Therapeutic Dosing Range of Teclistamab for Multiple Myeloma.
Girgis S, Lin SXW, Pillarisetti K, Banerjee A, Stephenson T, Ma X, Shetty S, Yang TY, Hilder BW, Jiao Q, Hanna B, Adams HC 3rd, Sun YN, Sharma A, Smit J, Infante JR, Goldberg JD, Elsayed Y. Girgis S, et al. Among authors: jiao q. Target Oncol. 2022 Sep;17(5):609. doi: 10.1007/s11523-022-00904-y. Target Oncol. 2022. PMID: 35913648 Free PMC article. No abstract available.
A novel C2 domain binding CD33xCD3 bispecific antibody with potent T-cell redirection activity against acute myeloid leukemia.
Nair-Gupta P, Diem M, Reeves D, Wang W, Schulingkamp R, Sproesser K, Mattson B, Heidrich B, Mendonça M, Joseph J, Sendecki J, Foulk B, Chu G, Fink D, Jiao Q, Wu SJ, Packman K, Elsayed Y, Attar R, Gaudet F. Nair-Gupta P, et al. Among authors: jiao q. Blood Adv. 2020 Mar 10;4(5):906-919. doi: 10.1182/bloodadvances.2019001188. Blood Adv. 2020. PMID: 32150609 Free PMC article.
Pharmacokinetics and safety of golimumab, a fully human anti-TNF-alpha monoclonal antibody, in subjects with rheumatoid arthritis.
Zhou H, Jang H, Fleischmann RM, Bouman-Thio E, Xu Z, Marini JC, Pendley C, Jiao Q, Shankar G, Marciniak SJ, Cohen SB, Rahman MU, Baker D, Mascelli MA, Davis HM, Everitt DE. Zhou H, et al. Among authors: jiao q. J Clin Pharmacol. 2007 Mar;47(3):383-96. doi: 10.1177/0091270006298188. J Clin Pharmacol. 2007. PMID: 17322150 Clinical Trial.
Absence of adverse effects in cynomolgus macaques treated with CNTO 95, a fully human anti-alphav integrin monoclonal antibody, despite widespread tissue binding.
Martin PL, Jiao Q, Cornacoff J, Hall W, Saville B, Nemeth JA, Schantz A, Mata M, Jang H, Fasanmade AA, Anderson L, Graham MA, Davis HM, Treacy G. Martin PL, et al. Among authors: jiao q. Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):6959-65. doi: 10.1158/1078-0432.CCR-04-2623. Clin Cancer Res. 2005. PMID: 16203788
A phase I, single and fractionated, ascending-dose study evaluating the safety, pharmacokinetics, pharmacodynamics, and immunogenicity of an erythropoietin mimetic antibody fusion protein (CNTO 528) in healthy male subjects.
Bouman-Thio E, Franson K, Miller B, Getsy J, Cohen A, Bai SA, Yohrling J, Frederick B, Marciniak S, Jiao Q, Jang H, Davis H, Burggraaf J. Bouman-Thio E, et al. Among authors: jiao q. J Clin Pharmacol. 2008 Oct;48(10):1197-207. doi: 10.1177/0091270008322907. J Clin Pharmacol. 2008. PMID: 18812609 Clinical Trial.
736 results